» Articles » PMID: 28761621

Toxicity and Immunogenicity in Murine Melanoma Following Exposure to Physical Plasma-Derived Oxidants

Overview
Publisher Wiley
Date 2017 Aug 2
PMID 28761621
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Metastatic melanoma is an aggressive and deadly disease. Therapeutic advance has been achieved by antitumor chemo- and radiotherapy. These modalities involve the generation of reactive oxygen and nitrogen species, affecting cellular viability, migration, and immunogenicity. Such species are also created by cold physical plasma, an ionized gas capable of redox modulating cells and tissues without thermal damage. Cold plasma has been suggested for anticancer therapy. Here, melanoma cell toxicity, motility, and immunogenicity of murine metastatic melanoma cells were investigated following plasma exposure in vitro. Cells were oxidized by plasma, leading to decreased metabolic activity and cell death. Moreover, plasma decelerated melanoma cell growth, viability, and cell cycling. This was accompanied by increased cellular stiffness and upregulation of zonula occludens 1 protein in the cell membrane. Importantly, expression levels of immunogenic cell surface molecules such as major histocompatibility complex I, calreticulin, and melanocortin receptor 1 were significantly increased in response to plasma. Finally, plasma treatment significantly decreased the release of vascular endothelial growth factor, a molecule with importance in angiogenesis. Altogether, these results suggest beneficial toxicity of cold plasma in murine melanomas with a concomitant immunogenicity of potential interest in oncology.

Citing Articles

Synergistic effects of cold atmospheric plasma and doxorubicin on melanoma: A systematic review and meta-analysis.

Rostami Z, Alizadeh-Navaei R, Golpoor M, Yazdani Z, Rafiei A Sci Rep. 2025; 15(1):7870.

PMID: 40050300 PMC: 11885813. DOI: 10.1038/s41598-025-90508-z.


Gas Plasma Technology and Immunogenic Cell Death: Implications for Chordoma Treatment.

Bekeschus S, Roessler K, Kepp O, Freund E Cancers (Basel). 2025; 17(4).

PMID: 40002275 PMC: 11852646. DOI: 10.3390/cancers17040681.


Rationales of Cold Plasma Jet Therapy in Skin Cancer.

Bekeschus S, Singer D, Ratnayake G, Ruhnau K, Ostrikov K, Thompson E Exp Dermatol. 2025; 34(2):e70063.

PMID: 39973132 PMC: 11840413. DOI: 10.1111/exd.70063.


Plasma-liquid interactions in the presence of organic matter-A perspective.

Stapelmann K, Gershman S, Miller V J Appl Phys. 2024; 135(16):160901.

PMID: 38681528 PMC: 11055635. DOI: 10.1063/5.0203125.


Current Status and Future Trends of Cold Atmospheric Plasma as an Oncotherapy.

Dai X, Wu J, Lu L, Chen Y Biomol Ther (Seoul). 2023; 31(5):496-514.

PMID: 37641880 PMC: 10468422. DOI: 10.4062/biomolther.2023.027.


References
1.
Wende K, Bekeschus S, Schmidt A, Jatsch L, Hasse S, Weltmann K . Risk assessment of a cold argon plasma jet in respect to its mutagenicity. Mutat Res Genet Toxicol Environ Mutagen. 2016; 798-799:48-54. DOI: 10.1016/j.mrgentox.2016.02.003. View

2.
Polette M, Gilles C, Nawrocki-Raby B, Lohi J, Hunziker W, Foidart J . Membrane-type 1 matrix metalloproteinase expression is regulated by zonula occludens-1 in human breast cancer cells. Cancer Res. 2005; 65(17):7691-8. DOI: 10.1158/0008-5472.CAN-04-4230. View

3.
Kluge S, Bekeschus S, Bender C, Benkhai H, Sckell A, Below H . Investigating the Mutagenicity of a Cold Argon-Plasma Jet in an HET-MN Model. PLoS One. 2016; 11(9):e0160667. PMC: 5008819. DOI: 10.1371/journal.pone.0160667. View

4.
Qin Y, Han Y, Cao C, Ren Y, Li C, Wang Y . Melanoma B16-F1 cells coated with fusion protein of mouse calreticulin and virus G-protein coupled receptor induced the antitumor immune response in Balb/C mice. Cancer Biol Ther. 2011; 11(6):574-80. DOI: 10.4161/cbt.11.6.14414. View

5.
Le Gal K, Ibrahim M, Wiel C, Sayin V, Akula M, Karlsson C . Antioxidants can increase melanoma metastasis in mice. Sci Transl Med. 2015; 7(308):308re8. DOI: 10.1126/scitranslmed.aad3740. View